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Bacterial and fungal infections represent a significant complica- 
ion in some viral diseases, such as influenza. 1 Since the onset of 
he coronavirus disease 2019 (COVID-19) pandemic, several stud- 
es have been published describing the epidemiology of infectious 
omplications of COVID-19. Co-infections, diagnosed around the 
ime of severe acute respiratory syndrome coronavirus 2 (SARS- 
oV-2) infection, appear to be uncommon occurring in 0.6 to 3.2% 
f patients. 2–5 Bacterial respiratory co-infections with Streptococ- 
us pneumoniae or Staphylococcus aureus are the most common 
auses of coinfections, whereas respiratory viral co-infections ap- 
ear to be relatively rare. 4 , 6 
In contrast, nosocomial superinfections appear to be more fre- 
uent than co-infections, particularly among patients admitted to 
he intensive care unit (ICU) and those receiving high doses of 
orticosteroids 4 , 6–9 . These patients develop high rates of blood- 
tream infections and ventilator-associated pneumonia. Addition- 
lly, emerging data have demonstrated unexpectedly high rates of 
ungal infections, such as candidemia and invasive aspergillosis, 
articularly among mechanically ventilated patients. 4 , 5 , 7 –10 Infec- 
ions due to multidrug-resistant (MDR) organisms have been re- 
orted some series. 9 Importantly, outcomes of patients with super- 
nfections are likely to be poor, with prolonged hospital stay 6 , 7 , 9 
nd higher mortality. 4 , 6 
Onco-hematological patients, including hematopoietic stem cell 
ransplant (HSCT) recipients are at a higher risk of acquiring 
OVID-19, 11 , 12 with the associated mortality reported to be higher 
han that in the general population. 12 , 13 Yet, there is scarce infor- 
ation regarding infectious complications in cancer patients with 307 Spain 
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ribe the epidemiology, risk factors, and clinical outcomes of co-infections
atological patients with COVID-19. 
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rinfections. 
luded (384 with solid tumors and 300 with hematological malignancies).
ns were documented in 7.8% (54/684) and 19.1% (113/590) of patients, re-
act infections were the most frequent infectious complications, most of-
umoniae and Pseudomonas aeruginosa . Only seven patients developed op-
d to patients without infectious complications, those with infections had
s of acute respiratory distress syndrome, intensive care unit (ICU) admis-
utropenia, ICU admission and high levels of C-reactive protein (CRP) were
ections. 
ations in cancer patients with COVID-19 were lower than expected, affect-
s with high levels of CRP and/or ICU admission. The rate of opportunistic
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OVID-19. Cancer as a comorbidity has been reported to be higher 
n patients with superinfections than in those without these com- 
lications. 4 , 9 However, there are only two studies that mention 
ery briefly the incidence and types of infectious complications. In 
 series of 536 patients with hematologic malignancies, of whom 
2 were allogeneic HSCT recipients, the only information provided 
as that 187 patients (34.8%) presented additional infections. 14 In 
nother series involving 77 HSCT recipients (37 allogeneic, 37 au- 
ologous, and five CAR T-cell recipients), ten patients developed in- 
ections (13%), caused by multiple organisms in some patients. 15 
he infections reported were bloodstream infections (BSIs) ( n = 3), 
ungal pneumonia ( n = 3), urinary tract infections (UTIs) ( n = 2), 
lostridioides difficile colitis ( n = 2), bacterial pneumonia ( n = 1) 
nd Epstein-Barr virus reactivation ( n = 1). Given these knowl- 
dge gaps, we designed an international multicenter cohort study 
f oncology patients with COVID-19. Our objectives were to define 
he epidemiology, risk factors and outcomes of infectious compli- 
ations in these individuals, with a focus on co-infections present 
t the time of COVID-19 diagnosis and superinfections developing 
ithin 48 h of admission. 
ethods 
tudy design and patients 
The COVICAN registry was an international, multicenter, com- 
ined prospective/retrospective, observational cohort study of adult 
atients with cancer and COVID-19, across 28 hospitals from 9 
ountries in Europe, North America and South America from 1 
arch 2020 to 30 June 2020 (COVICAN registry). A list of the par- 
icipating centers is provided in the Supplementary Material. All 
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Table 1 
Baseline characteristics of patients with co-infections at COVID-19 diagnosis. 
Characteristic No co-infection N = 630 (%) Co-infection N = 54 (%) P value Adjusted OR (95% CI) P value 
Age, years (median, IQR) 67 (18–95) 67.5 (20–88) 0.42 0.98 (0.93–1.02) 0.40 
Male sex 364 (57.8) 31 (57.4) 1.00 1.52 (0.39–5.91) 0.54 
Hematological malignancy 276 (43.8) 24 (44.4) 1.00 
Lymphoma 88 (14) 10 (18.5) 
Multiple myeloma 58 (9.2) 5 (9.3) 
Acute leukemia 40 (6.3) 3 (5.6) 
Myelodysplastic syndrome 21 (3.3) 2 (3.7) 
Chronic lymphocytic leukemia 48 (7.6) 3 (5.6) 
Hematopoietic stem cell transplant 54 (19.6) 2 (8.3) 
Solid tumor 354 (56.2) 30 (56.6) 1.00 
Lung cancer 82 (23.2) 3 (10) 
Breast cancer 60 (17) 5 (16.7) 
Colorectal cancer 58 (16.4) 2 (6.7) 
Upper GI tract cancer 24 (6.8) 2 (6.7) 
Urinary tract cancer 21 (5.9) 2 (6.7) 
Gynecological cancer 14 (4) 5 (16.7) 
Prostate cancer 29 (8.2) 3 (10) 
Head and neck cancer 16 (4.5) 3 (10) 
Hepatobiliary tumor 22 (6.2) 2 (6.7) 
Others 19 (3.01) 3 (5.5) 
Comorbidities 
Hypertension 290 (46.1) 28 (51.9) 0.47 
Diabetes mellitus 127 (20.3) 10 (18.9) 1.00 
COPD 52 (60.5) 4 (44.4) 0.48 
Chronic heart disease 23 (3.7) 2 (3.7) 1.00 
Chronic renal disease 21 (3.3) 1 (1.9) 1.00 
Immunosuppressive therapy 
Previous corticosteroids (1 month) 155 (24.8) 18 (33.3) 0.15 
Prednisone > 10 mg/day 91 (59.9) 8 (44.4) 0.21 
Immunotherapy/targeted therapies 130 (20.6) 10 (18.5) 0.86 
Monoclonal antibodies 35 (5.6) 4 (7.4) 0.53 
Neutropenia ( < 500 cells/mm 3 ) 25 (4.3) 9 (18) 0.001 2.99 (0.99–9.06) 0.052 
Inflammatory biomarkers (median, IQR) 
C-reactive protein (mg/L) 77.4 (0.08–580) 129 (3–629) 0.019 1.00 (1.00–1.02) 0.022 
Procalcitonin ( μg/L) 0.14 (0.0–105) 0.19 (0.03–80.9) 0.2 
Ferritin ( μg/L) 831 (2.4–35,854) 1.343 (12.4–36.079) 0.22 
Creatine kinase (U/L) 56 (0.94–1.549) 56.5 (9–2.344) 0.31 
Antibacterial therapy 480 (78.4) 45 (88.2) 0.098 
Amoxicillin-clavulanate 58 (12.1) 6 (13.3) 0.81 
Broad-spectrum cephalosporins 64 (13.3) 3 (6.7) 0.24 
Carbapenems 91 (19) 17 (37.8) 0.006 
Quinolones 33 (6.9) 2 (4.4) 0.75 
Piperacillin-tazobactam 111 (23.1) 17 (37.8) 0.044 
Antifungal therapy 12 (2) 3 (5.9) 0.10 
Acute respiratory distress syndrome 185 (30.7) 29 (56.9) < 0.001 
Intensive care unit admission 77 (12.7) 8 (15.7) 0.51 
Overall in-hospital case fatality rate 187 (30.6) 28 (53.8) < 0.001 
COPD, Chronic obstructive pulmonary disease; Broad-spectrum cephalosporins: cefepime, ceftazidime, ceftolozane-tazobactam and ceftazidime- 
avibactam; Antifungal therapy (more than one antifungal was administered in some patients): fluconazole ( n = 5), anidulafungin ( n = 3), voriconazole 
































atients had an active malignancy or were HSCT recipients with 
OVID-19, defined as symptoms of COVID-19 with a positive real- 
ime reverse transcription PCR (RT-PCR) nasopharyngeal or oropha- 
yngeal swab test. Active cancer was defined as metastatic cancer 
r anticancer treatment in any setting (curative, radical, adjuvant, 
r neoadjuvant) or administration of with cytotoxic chemotherapy 
r radiotherapy within the past 6 months. The COVICAN registry 
as built and maintained as an electronic REDCap database housed 
t Bellvitge University Hospital. Data collection was either retro- 
pective or prospective. All patients were included in the analysis 
f co-infections at diagnosis, while only patients admitted for at 
east 48 h were included in the analysis of superinfections that 
eveloped during hospitalization. The study was approved by the 
nstitutional Review Board of Bellvitge University Hospital (refer- 
nce number PR133/20) and by the research ethics committees of 
he participating centers. Furthermore, it was conducted according 
o the guidelines of the Declaration of Helsinki. The need for in- 
ormed consent was waived for retrospective cases by the clinical esearch ethics committees. 
n
w
308 ata collection and procedures 
We collected data on demographics, comorbidities, cancer sta- 
us and therapy, laboratory tests, microbiological results (cultures 
nd non-culture diagnostics such as fungal biomarkers and viral 
CR results), treatment, and outcomes. All testing and treatment 
as conducted as routine care by the individual centers. 
efinitions 
Co-infections or nosocomial superinfections were defined as in- 
ections occurring at COVID-19 diagnosis or after 48 h of hospital 
dmission for COVID-19, respectively. Neutropenia was defined as 
n absolute neutrophil count < 500 per mm 3 . 
Infectious were defined using the Centers for Disease Control 
ational Healthcare and Safety Network 16 . A bloodstream infection 
BSI) was defined as the growth of bacteria or fungi in at least one 
lood culture. BSIs caused by skin colonizers such as coagulase- 
egative staphylococci (CoNS) were considered to be significant 
hen the pathogens grew in two or more blood cultures drawn 


























































Type and microbiological etiology of 54 co-infections occur- 
ring in 54 cancer patients at COVID-19 diagnosis. 
Co-infections at COVID-19 diagnosis N (54/684 (7.8%)) 
Respiratory tract infections a 21 (38.8%) 
Streptococcus pneumoniae b 9 
Moraxella catarrhalis 3 
Haemophilus influenzae c 3 
Pseudomonas aeruginosa 3 
E. coli d 1 
Klebsiella pneumoniae 1 
Enterobacter cloacae 1 
Serratia marcescens 1 
Staphylococcus aureus e 1 
Bacteremia f 18 (33.3%) 
E. coli 5 
Viridans group streptococci 3 
Enterococcus faecium 2 
P. aeruginosa 1 
Listeria monocytogenes 1 
Capnocytophaga sputigena 1 
S. aureus 1 
Catheter-related bacteremia 6 
Coagulase-negative staphylococci 6 
Micrococcus letis 1 
Urinary tract infection g 15 (27.7%) 
E. coli h 9 
K. pneumoniae 2 
Enterococcus faecalis 2 
Klebsiella oxytoca 1 
Proteus mirabilis 1 
P. aeruginosa 1 
Enterobacter aerogenes 1 
Enterococcus faecium 1 
a Two episodes were polymicrobial: E. coli + Streptococcus 
pneumoniae ( n = 1), and Serratia marcescens + Enterobacter 
cloacae ( n = 1). 
b Eight episodes were diagnosed by the pneumococcal uri- 
nary antigen test. 
c Two episodes were diagnosed by positive blood cultures. 
d This episode was associated with bacteremia. 
e Positive culture from pleural effusion. 
f Three episodes were polymicrobial: E. coli + viridans 
group streptococci ( n = 1), E. coli + Enterococcus faecium ( n 
= 1), and Pseudomonas aeruginosa + Staphylococcus aureus ( n 
= 1). 
g Three episodes were polymicrobial: Klebsiella oxytoca + E. 
faecium ( n = 1), E. coli + E. faecalis ( n = 1), and P. aeruginosa 
+ Proteus mirabilis ( n = 1). 





















rom different sites. Catheter-related BSIs were diagnosed in pa- 
ients using at least one of the following criteria: (1) positive pe- 
ipherally drawn blood cultures and positive blood cultures drawn 
rom any of the catheter lumens; (2) time to positivity of at least 
20 min for catheter-drawn blood cultures; or (3) positive culture 
f the same microorganism as that isolated from the catheter tip. 
pisodes of polymicrobial BSIs were those in which more than one 
ype of organism was isolated from one or more blood cultures 
ithin a 72 h period. Bacterial respiratory infections were diag- 
osed in patients with one or more positive cultures of respiratory 
athogens obtained from the blood, pleural fluids, sputum, bron- 
hoalveolar lavage, and tracheal aspirate and/or a positive urinary 
. pneumoniae antigen test. Other respiratory pathogens such as in- 
uenza A and B viruses, respiratory syncytial virus, parainfluenza 
irus and metapneumovirus were also studied in respiratory sam- 
les, based on the requests of the attending physician. Respira- 
ory infections without microbiological diagnosis were considered 
n patients with the following criteria: (1) fever; (2) respiratory 
ymptoms; (3) new pulmonary infiltrates; (4) exclusion of other 
on-infectious causes of pulmonary infiltrates. A urinary infection 
as defined as the growth of bacteria or fungi in a cultured urine 
ample from a patient with clinical symptoms and/or when a uri- 
ary infection was considered to be clinically significant by the re- 
earchers. 
Aspergillus spp . tracheobronchitis was indicated by the isolation 
f Aspergillus species from respiratory samples of patients with pu- 
ulent secretions and no radiological images. Invasive aspergillo- 
is was diagnosed as possible, probable or proven according to 
ORCT/MSGERC criteria. 17 
tatistical analysis 
Descriptive statistics were used to determine characteristics of 
atients and infections. To compare the characteristics, risk fac- 
ors and outcomes between infected and non-infected patients, 
he Mann-Whitney U Fisher test, chi-square and Fisher exact tests 
ere used for categorical and continuous variables, as appropri- 
te. Patients with and without co-infections were compared in a 
nivariate analysis in order to identify potential risk factors for 
o-infection at COVID-19 diagnosis. Similarly, patients with and 
ithout superinfections were compared in a univariate analysis 
n order to identify potential risk factors for superinfections dur- 
ng hospitalization. Multivariate logistic regression analyses were 
erformed to identify independent risk factors for co-infections 
nd superinfections, using variables that achieved statistical signif- 
cance in the univariate analysis. P -values < 0.05 were considered 
ignificant. 
esults 
A total of 684 patients were included, all of whom had data 
vailable about co-infections with COVID-19; 590 of these patients 
lso had follow-up data for nosocomial superinfections. Three hun- 
red patients had an underlying hematological malignancy; lym- 
homa (32.6%, 98/300) and multiple myeloma (20.6%, 62/300) 
ere the most common conditions ( Table 1 ). Among the 384 pa- 
ients with solid tumors, lung (22.1%, 85/384) and breast cancer 
16.9%, 62/384) were the most frequent malignancies ( Table 1 ). 
o-infections at COVID-19 diagnosis 
Overall, 7.8% (54/684) of patients presented with co-infections. 
he characteristics of patients with and without co-infections are 
hown in Table 1 . There were no relevant differences in the base- 
ine characteristics of the patients. However, higher levels of C- 
eactive protein (CRP) and the presence of neutropenia at diagnosis 309 ere more frequently reported in patients with co-infections. An- 
ibiotic therapy was more frequently administered in this group of 
atients, particularly carbapenems (37.8% vs 19%, p = 0.006) and 
iperacillin-tazobactam (37.8% vs 23.1%, p = 0.044). Patients with 
o-infections were more likely to present worse outcomes, with 
igher rates of acute respiratory distress syndrome (56.9% vs 30.7%, 
 < 0.001) and a higher overall in-hospital case-fatality rate (53.8% 
s 30.6%, p = 0.001). 
Table 2 details the types and etiologies of the 54 co-infections 
dentified at COVID-19 diagnosis. All co-infections were bacte- 
ial. Respiratory tract infections were the most common (38.8%), 
ollowed by BSIs (33.3%). Streptococcus pneumoniae and Gram- 
egative bacilli (which included three cases of Pseudomonas aerug- 
nosa ) were the most common causes of respiratory tract infec- 
ions (42.8% (9/21) and 33.3% (7/21), respectively). Eighty nine per- 
ent of S. pneumoniae pneumonias were diagnosed by urinary anti- 
en test. Three episodes were associated with BSI ( Haemophilus in- 
uenzae ( n = 2) and Escherichia coli ( n = 1)), and two episodes
ere polymicrobial. Among BSI episodes, catheter-related BSIs due 
o CoNS were the most common cause (33.3%, 6/18), followed by 
. coli (27.7%, 5/18) and viridans group streptococci (VGS) (16.6%, 
























































































































/18). Three episodes of BSI were polymicrobial. Among the UTIs, 
. coli was the most common pathogen (60%), and three episodes 
ere polymicrobial. 
The risk factors for co-infections at COVID-19 diagnosis are also 
hown in Table 1 . By univariate analysis, higher levels of CRP and 
he presence of neutropenia at COVID-19 diagnosis were more fre- 
uently seen in patients with co-infections. In multivariate logistic 
egression, neutropenia was found to be the only significant inde- 
endent risk factor for co-infections at COVID-19 diagnosis. 
uperinfections during hospitalization 
Overall, 82 patients developed 113 superinfections during hos- 
italization (19.1%). Table 3 outlines the characteristics, outcomes 
nd risk factors of patients with and without superinfections dur- 
ng hospitalization. Patients with hematologic malignancies, partic- 
larly those with lymphoma, were more likely to develop superin- 
ections than those with solid tumors (57.3% vs. 42.7%, p = 0.023). 
atients treated with immunotherapy or targeted therapies in the 
revious 3 months were less likely to present superinfections than 
hose were not (11% vs. 22.4%, p = 0.018). In contrast, neutrope- 
ia (10.8% vs. 4.2%, p = 0.04), and the use of corticosteroids for 
he treatment of COVID-19 (48.1% vs. 36.9%, P = 0.049), were sig- 
ificantly more common in patients presenting with superinfec- 
ions. In multivariate analysis, only neutropenia and ICU admission 
ere found to be independent risk factors for developing a super- 
nfection during hospitalization. Antibiotic and antifungal therapies 
ere more frequently administered in this group of patients, par- 
icularly carbapenems (44.3% vs. 16.2%, p < 0.001) and piperacillin- 
azobactam (36.7% vs. 22.2%, p = 0.010). Patients with superin- 
ections had poorer outcome than those without superinfections, 
ith higher rates of acute respiratory distress syndrome (44.3% vs. 
1.3%, p = 0.028), ICU admission (35% vs. 10.1%, p < .001), and in-
asive mechanical ventilation (33.8% vs. 5.9%, p < 0.001), as well as 
igher ICU-associated case-fatality rates (14.1% vs 4.7%, p = 0.003). 
The types and etiologies of the 113 episodes of superinfections 
ccurring in 82 cancer patients are detailed in Table 4 . Respira- 
ory tract infections were the most frequent infectious complica- 
ions (46/113, 40.7%). In 17 cases (36.9%), no microorganisms were 
dentified. Gram-negative bacteria accounted for more than half 
f the cases (52.1%), with P. aeruginosa being the most common 
34.7%). Aspergillus fumigatus was the etiological agent in three 
ases of tracheobronchitis (one polymicrobial with P. aeruginosa ). 
nly seven cases of opportunistic infections developed, including 
ve cases of cytomegalovirus viremia, one case of probable invasive 
ulmonary aspergillosis (IPA) and one case of BK polyomavirus- 
ssociated hemorrhagic cystitis. Only six infections were caused 
y MDR organisms: three due to MDR P. aeruginosa , two due 
o methicillin-resistant S. aureus and one caused by extended- 
pectrum ß-lactamase-producing Enterobacter spp . 
iscussion 
In our large multinational cohort of onco-hematological pa- 
ients with COVID-19, we found that the rate of co-infections at the 
ime of diagnosis was more than double the rate reported in the 
eneral population 2 –5 but the rate of superinfections was compa- 
able to those observed in previous reports in the general popula- 
ion. 6 –9 Neutropenia was a major risk factor for both co-infections 
nd superinfections, whereas ICU admission was also a risk factor 
or superinfections. Surprisingly, no respiratory viral co-infections 
ere encountered, and the rate of opportunistic infections, partic- 
larly IPA, was unexpectedly low. Nevertheless, patients with co- 
nfections and/or superinfections presented worse outcomes, with 
igher case fatality rates. Taken together, our data highlight the 
eed for improved diagnostics to identify patients at highest risk 310 or infections following COVID-19, in order to prioritize these pa- 
ients for antimicrobial therapy. 
Although there are some published studies involving large co- 
orts of onco-hematological patients with COVID-19, data on the 
ates, characteristics and outcomes of infectious complications in 
his population are lacking. 14 , 15 , 18 –21 This is of special concern 
ince cancer patients are at a higher risk of acquiring COVID- 
9. 11 , 12 Due to their often severely impaired immune system, it has 
een widely assumed that the risk of developing additional infec- 
ious complications is high. As a consequence, it has been reported 
hat the number of antimicrobial prescriptions in cancer patients 
ith COVID-19 has been high, 18 –21 even in patients showing no 
vidence of infectious complications during hospitalization, which 
eached 81.5% in our study. This is of special concern in the cur- 
ent era of emerging antimicrobial resistance, since a reduction of 
ntibiotic consumption is a cornerstone in the fight against the de- 
elopment of resistance. 
In our series, co-infections mainly occurred in patients with 
eutropenia and high levels of CRP. These included both bacterial 
o-infections commonly encountered in cancer patients ( S. pneu- 
oniae, P. aeruginosa ), as well as BSIs, which are common in can- 
er patients due to the presence of indwelling catheters, mucositis, 
nd neutropenia. 22 , 23 These findings suggest that antibiotics may 
ot need to be administered to all cancer patients who present 
ith COVID-19, but may instead be targeted more to those with 
eutropenia and elevated CRP levels. No other respiratory viruses 
ere identified, although this may have been a result of limited 
iagnostic testing in 2020, due to swab and PCR reagent shortages. 
Nearly 20% of patients developed nosocomial superinfections, 
hich was lower than we had originally expected, as many 
atients had previously received immunosuppressive therapies 
nd/or immunomodulatory treatments for COVID-19. This finding 
ay be a result of limitations in diagnostic testing in patients who 
re under COVID-19 transmission-based precautions. ICU stay and 
eutropenia were risk factors for superinfections, further suggest- 
ng that even among hospitalized patients, empiric antibiotics may 
otentially be withheld for most individuals, except for critically ill 
atients and those with neutropenia. Additional studies are needed 
o help optimize antibiotic use in critically ill neutropenic cancer 
atients, in whom distinguishing between respiratory failure and 
ever from COVID-19 versus an underlying bacterial infection can 
e difficult. 
Interestingly, opportunistic infections were unexpectedly rare, 
ith only one case of documented IPA, although three patients 
ere diagnosed with Aspergillus tracheobronchitis. The rates of 
OVID-19-associated pulmonary aspergillosis (CAPA) reported in 
he literature vary greatly, ranging from 0.1 to 47.4%. 24–28 We hy- 
othesize that these findings may be explained by the challenges 
ncountered in diagnosing CAPA: diagnostic criteria are poorly- 
efined, the radiological findings are often non-specific in individ- 
als with concurrent COVID-19 pneumonia, testing may be infre- 
uently sent due to lack of clinician awareness, the performance of 
ungal biomarkers assays in CAPA is unknown (although the galac- 
omannan assay is expected to have a good performance in neu- 
ropenia), and it is difficult to distinguish colonization from infec- 
ion. Nonetheless, the rate of IPA observed in patients with COVID- 
9, even when they carry a baseline immunosuppressive condition 
such as our patients), appears to be much lower than that ob- 
erved in patients with influenza. 12–13 Other invasive fungal infec- 
ions, such as Candida , were not observed in our cohort compared 
o other reports. 29–30 
The in-hospital case-fatality rate in our cohort was 32.4% 
215/664), which is significantly higher than that reported for the 
eneral population, but in line with several other reports involv- 
ng cancer patients. 18–21 Patients with infectious complications in 
ur study had worse outcomes, higher rates of acute respiratory 
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Table 3 
Main characteristics of 82 patients with superinfections after 48 h of hospitalization for COVID-19. 
Characteristic 
Patients without a 
superinfection 
N = 508 (%) 
Patients with a 
superinfection 
N = 82 (%) P value 
Adjusted ∗ OR (95% 
CI) P value 
Age, years (median, IQR) 67 (40–84) 47 (22–72) 0.084 0.98 (0.95–1.00) 0.011 
Male sex 278 (54.7) 55 (67.1) 0.041 0.93 (0.45–1.92) 0.85 
Hematological malignancy 219 (43.1) 47 (57.3) 0.023 1.07 (0.49–2.31) 0.85 
Lymphoma 66 (13) 19 (23.2) 
Acute leukemia 29 (5.7) 9 (11) 
Multiple myeloma 52 (10.2) 6 (7.3) 
Myelodysplastic syndrome 15 (3) 1 (1.2) 
Chronic lymphocytic leukemia 40 (7.9) 7 (8.5) 
Hematopoietic stem cell transplant 44 (20.1) 6 (12.8) 
Solid tumor 289 (57) 35 (42.7) 0.023 
Lung cancer 56 (19.4) 7 (20) 
Breast cancer 60 (20.8) 0 
Colorectal cancer 53 (18.4) 4 (11.4) 
Prostate cancer 22(7.6) 6 (17.1) 
Upper GI tract cancer 19 (6.6) 1 (2.9) 
Urinary tract cancer 16 (5.6) 3 (8.6) 
Gynecological cancer 13 (4.5) 5 (16.7) 
Head and neck cancer 9 (3.1) 4 (11.4) 
Hepatobiliary tumor 15 (5.1) 5 (14.3) 
Other 15 (5.1) 0 
Comorbidities 
Hypertension 241 (47.5) 39 (47.6) 1.00 
Diabetes mellitus 99 (19.6) 15 (18.3) 0.88 
COPD 37 (57.8) 10 (55.6) 1.00 
Chronic heart disease 19 (3.7) 4 (4.9) 0.54 
Chronic renal disease 14 (2.8) 4 (4.9) 0.30 
Immunosuppressive therapy 
Previous corticosteroids (1 m) 130 (25.7) 23 (28) 0.68 
-Prednisone > 10 mg/day 75 (58.6) 13 (59.1) 1.00 
Immunotherapy/targeted therapies 114 (22.4) 9 (11) 0.018 0.50 (0.17–1.43) 0.20 
Monoclonal antibodies 29 (5.7) 7 (8.5) 0.32 
Neutropenia ( < 500 cells/mm 3 ) 20 (4.2) 8 (10.8) 0.040 4.88 (1.35–17.5) 0.015 
Inflammatory biomarkers (median, IQR) 
C-reactive protein (mg/L) 65 (12–250) 79.4 (13–381) 0.16 1.00 (1.00–1.00) 0.12 
Procalcitonin ( μg/L) 0.10 (0.02–3.94) 0.24 (0.11–2.00) 0.94 
Ferritin ( μg/L)) 1.247 (30–12.474) 654 (466–11,330) < 0.001 
Creatine kinase (U/L) 66 (16–296) 85 (16–185) 0.54 
Therapy 
Hydroxychloroquine 375 (92.4) 60 (83.3) 0.023 
Lopinavir/ritonavir 222 (54.7) 44 (61.1) 0.36 
Remdesivir 15 (3.7) 6 (8.2) 0.11 
Tocilizumab 75 (18.5) 18 (25) 0.20 
Corticosteroids 185 (36.4) 39 (48.1) 0.049 2.03 (0.96–4.30) 0.062 
Corticosteroids and/or immunomodulators 204 (40.2) 42 (51.9) 0.053 
Antibacterial therapy 414 (81.5) 79 (97.5) < 0.001 
Amoxicillin-clavulanate 52 (12.6) 9 (11.4) 0.85 
Broad-spectrum cephalosporins 51 (12.3) 16 (20.3) 0.059 
Carbapenems 67 (16.2) 35 (44.3) < 0.001 
Quinolones 25 (6) 8 (10.1) 0.21 
Piperacillin-tazobactam 92 (22.2) 29 (36.7) 0.010 
Antifungal therapy 9 (1.8) 5 (6.2) 0.032 
Acute respiratory distress syndrome 158 (31.3) 35 (44.3) 0.028 
ICU admission 51 (10.1) 28 (35) < 0.001 4.98 (2.26–10.9) < 0.001 
Invasive mechanical ventilation 30 (5.9) 27 (33.8) < 0.001 
Overall in-hospital case-fatality rate 157 (31.3) 26 (32.5) 0.89 
ICU-associated case-fatality rate 23 (4.7) 11 (14.1) 0.003 
ICU, intensive care unit. COPD, Chronic obstructive pulmonary disease; Broad-spectrum cephalosporins: cefepime, ceftazidime, ceftolozane-tazobactam and ceftazidime- 
avibactam; Antifungal therapy (more than one antifungal was administered in some patients): fluconazole ( n = 5), voriconazole ( n = 3), micafungin ( n = 3), caspofungin 





















istress syndrome, ICU admission, and increased mortality. These 
ndings are consistent with those of previous reports of oncol- 
gy patients with respiratory viral infections. 4 , 6 , 7 , 9 However, there 
re several variables that may influence the outcomes of cancer 
atients with COVID-19, particularly the presence of uncontrolled 
nderlying malignancy. Thus, these worse outcomes cannot be en- 
irely attributed to the development of infectious complications. 
Limitations of the study include its partial retrospective de- 
ign and the fact that diagnostic testing was performed accord- 
ng to the discretion of the individual sites. Our rate of infection 
ay be falsely low, particularly in the setting of enhance COVID-19 311 ransmission-based precautions limiting the ability of clinicians to 
erform diagnostic tests for infection. Additionally, systematic test- 
ng for viral co-infections was not performed by all participating 
enters. Despite these limitations, ours is the first published report 
ddressing infectious complications in immunocompromised can- 
er patients with COVID-19. We include data for a large number 
f patients from 28 centers located in nine countries around the 
orld, thereby improving the generalizability of our results. 
In conclusion, in our large multinational cohort of cancer pa- 
ients with COVID-19, co-infections were higher than in the gen- 
ral population, mainly affected neutropenic patients and critically 
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Table 4 
Detailed microbiological etiology of 113 superinfections occurring in 82 can- 
cer patients after 48 of hospitalization for COVID-19. 
Superinfections during hospitalization for COVID-19 113/590 (19.1%) 
Ventilator-associated pneumonia 10 (8.8%) 
Pseudomonas aeruginosa 5 
Enterobacter aerogenes + Burkholderia cepacia 1 
Not identified 4 
Non-ventilator-associated pneumonia a 18 (15.9%) 
Streptococcus pneumoniae 3 
Pseudomonas aeruginosa 2 
Haemophilus influenzae 1 
E. coli 1 
Stenotrophomonas maltophilia 1 
Not identified 11 
Nosocomial tracheobronchitis b 18 (15.9%) 
P. aeruginosa 9 
Aspergillus fumigatus 3 
Staphylococcus aureus 2 
Enterobacter aerogenes 2 
E. coli 1 
S. maltophilia 1 
Acinetobacter baumannii 1 
Not identified 2 
Bacteremia c 31 (27.4%) 
E. coli 4 
P. aeruginosa 3 
Enterococcus faecalis 2 
Enterococcus faecium 1 
Viridans group streptococci 1 
Candida albicans 1 
Catheter-related bacteremia 20 
Coagulase-negative staphylococci 16 
E. faecium 3 
E. faecalis 2 
P. aeruginosa 1 
Candida parapsilosis 1 
Urinary tract infection d 17 (12.7%) 
E. faecium 4 
E. faecalis 3 
E. coli 3 
P. aeruginosa 3 
Proteus mirabilis e 2 
Staphylococcus aureus 1 
Citrobacter koseri 1 
Candida krusei 1 
Candida glabrata 1 
Candida parapsilosis f 1 
Clostridium difficile colitis 6 (5.3%) 
Other bacterial infections 4 (3.5%) 
Biliary tract infections g 3 
Peritonitis 1 
Opportunistic infections 7 (6.1%) 
Invasive pulmonary aspergillosis 1 
Cytomegalovirus viremia 5 
BK polyomavirus-associated hemorrhagic cystitis 1 
a One episode was polymicrobial: E. coli + Streptococcus pneumoniae 
( n = 1). 
b Three episodes were polymicrobial: E. coli + Pseudomonas aeruginosa 
( n = 1), P. aeruginosa + Aspergillus fumigatus ( n = 1), and Staphylococcus 
aureus + Enterobacter aerogenes ( n = 1). 
c Four episodes were polymicrobial: Enterococcus faecium + P. aeruginosa 
( n = 1), Enterococcus faecalis + Candida parapsilosis ( n = 2), and E. fae- 
calis + Staphylococcus haemolyticus ( n = 1). 
d Two episodes were polymicrobial: E. faecium + P. aeruginosa ( n = 1), 
and E. faecalis + P. aeruginosa ( n = 1). 
e This episode was bacteremic. 
f This was an episode of candidemia. 



























ll ICU patients, and were associated with severe disease and poor 
utcomes. Further studies are needed to define the risk factors for 
acterial and fungal infections in oncology patients with COVID-19 
o better optimize antimicrobial use in these vulnerable individu- 
ls, and avoid unnecessary antibiotic exposure. 312 eclaration of Competing Interest 
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